CD274 and gastric cancer: Moreover, in patients with PD‐L1 CPS ≥1, this triple treatment regimen showed a dramatically better objective response rate than those with negative PD‐L1 expression,15 suggesting that PD‐L1 is also the vital therapeutic target for patients with advanced or metastatic GC.